INTRODUCTION
A number of articles reviewing the safety of blood derivatives have appeared recently [1] [2] [3] [4] [5] . For the most part, these have given an overview of the various methods currently employed to inactivate viruses together with a comparison of their effectiveness, based on animal and clinical study results. This paper will examine the issue from a different perspective, one that is more theoretical and statistical, in which predicted rates of infectivity of various products for blood-borne viruses are calculated based on information concerning viral loads and compared with the actual published incidence data. By doing so, it is hoped that we will be better able to judge whether the current generation of coagulation factor concentrates are truly safe with regard to the transmission of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV; formerly non-A, non-B hepatitis virus), the viruses of principal concern in blood protein derivatives.
ALBUMIN SAFETY As a consequence of pasteurization, combined with methods of purification which remove virus, albumin solutions have achieved an admirable record of virus safety [6] . The decision to prescribe and infuse albumin solutions today rests solely on issues of Analysis of virus safety requires an appreciation of the initial viral load, the extent to which virus is removed during processing, serendipitous inactivation which occurs during processing and/or storage, the efficacy of the inactivation method employed, and host susceptibility factors. Provided we are willing to accept a degree of uncertainty, an estimate of each for HBV is provided in Table 1 for susceptible hosts [1, [7] [8] [9] [10] [11] [12] . Prior to implementation of screening assays for HBsAg, both the proportion of units containing infectious HBV and the titer of HBV contained in infectious units was substantially higher than that observed today. Under this circumstance, the probability that a vial of albumin would contain infectious HBV is calculated at 3 x 10-6. Phrased differently, one vial per 300,000 is predicted to contain infectious HBV. This calculation is in good agreement with the occasional, but rare, outbreak of hepatitis B arising from albumin prepared from unscreened donors. With inclusion of HBsAg screening, the number of vials/ID50 exceeds 109. This corresponds to the well-documented belief that albumin is safe [6] .
While this analysis of safety may appear to be esoteric, it should be accepted with the same confidence as is recognized when assessing methods of bacterial sterilization, such as by autoclaving, sterile filtration, ultraviolet irradiation, and the like. In the case of albumin manufacture and HBV transmission, it is important to understand that albumin's large margin of safety arises from a combination of factors operating in concert (Fig. 1) [29] . Consequently, on filling, one out of four vials would be expected to contain infectous HIV. A similar calculation performed for both HBV and HCV predicts that 30,000 vials would contain one ID50 of HBV and 1/0.03 vials (i.e., 40 ID50/vial) would contain infectious HCV. Based on these estimates, a hemophiliac treated for one year with 80,000 units of coagulant in the form of these concentrates would have a probability of being exposed to HIV, HBV, and HCV of, respectively, 100 percent, 0.3 percent, and 100 percent. Actual transmission rates are in accord with these calculated values [6, 14, 15, [17] [18] [19] . Of interest, as [7] . This suggests a per unit risk prior to screening of 0.37 percent. Furthermore, commercially obtained blood was reported to carry a threefold higher hepatitis risk [35] . In a transfusion setting, if the ratio of volunteer to commercial blood was 2:1, then the overall risk from unselected, unscreened donors was 0.6 percent.
Results from the transfusion-transmitted viral disease study in 1981 indicated that 0.27 percent of screened, mostly voluntarily donated units were associated with HBV transmission [36] . Implementation of more rigorous donor selection criteria, ALT and anti-HBc testing, and donor education have lowered HBV transmission further [21, 40, 48] . Line 3: The number of Dane particles in HBsAg-positive sera varies widely [10] . Almeida [37] concluded that the sera of most chronic carriers contained about 105 Dane particles/mL.
Inclusion in a plasma pool of an occasional infectious unit such as shown by Barker et al. [9] to contain 1075 ID50 would raise the overall average.
The sensitivity limit of current tests for HBsAg [38] suggests that up to 103 ID50/mL of HBV could be in a unit which tests negative. Line 4: Line 1 x line 2 x 250 mL/unit x line 3 Line 5: In one study [4] , a 1.3 log,o removal and, in a second study [11] , a 2.6 loglo removal of HBsAg were reported. Dane particle removal may exceed the removal of HBsAg, since neither DNA polymerase nor Dane particles were detected in fraction V (albumin) [11] . Line 6: Anti-HBs (0.4 IU/mL) addition prevented HBV transmission to chimpanzees when added to plasma containing approximately 5 x 104 ID50 of HBV or to purified fractions from this plasma [12] . An additional inactivation of 10 5 during cold ethanol fractionation is assumed. application of even a modestly effective virucidal procedure, e.g., one that inactivates 103 ID50, is calculated to provide rates of infectivity which approach zero. This rate compares well with the observed transmission rates; 2/157 and 0/35 carefully monitored patients were infected with HIV and HBV, respectively (Table 3A) . Application of the same virucidal procedure to the quantity of HCV estimated to be present, 40,000 ID50, is not, however, sufficient to yield an HCV-safe product. This prediction is borne out by the observation that 29/67 of patients developed signs of HCV infection during the course of several months of treatment (Table 3A) . In contrast, highly virucidal methods, defined as those shown or likely to inactivate >105 ID50 of HIV, HBV, and HCV (Table 3B) , are predicted to provide a product found to be safe in clinical transmission studies, and such has been the case. HBV and HCV transmission has occurred rarely and, where observed, may well represent transmission by community vectors and not by product. What, then, is the predicted viral safety of modern coagulation factor concentrates?
Adoption of the solvent/detergent inactivation method [30, 31] or another similarly potent virucidal procedure, when coupled with improvements in donor screening and product purification, is calculated to increase the vials/ID50 to >1016 for HIV, >10'3 for HBV, and to >106 for HCV (Table 4 ). This rate compares favorably with the predicted HBV safety of albumin (Fig. 2) HIV-The mean titer of HIV in filtered plasma from asymptomatic patients and in AIDS patients was reported to be 10'4 and 102.5 TCID_0/mL, respectively [43] . In a more recent study, HIV titers in plasma for patients with asymptomatic infections, AIDS, or ARC were, respectively, 30, 3,500, and 3,200 TCID50/mL [251. Viral titers of infectious plasma placed into fractionation might be higher than these values as a result of leukocyte contamination. For asymptomatic patients, 20 per million peripheral blood mononuclear cells had isolatable virus [25] . HBV-Refer to Table 1. HCV-Chronic-phase plasma has been reported to contain infectious titers of 10'-103/mL [28] . Acute-phase plasma can contain 106 ID50/mL, but this has been rare [3] . [44] . Aluminum hydroxide adsorption and subsequent purification by precipitation have been reported to remove/inactivate approximately 1 log each of other retroviruses [29] .
Cryoprecipitation removes 1.9 log10 of HBsAg [39] .
The fractionation characteristics of HCV are unknown at this time. Line 6: Serendipitous inactivation during processing is uncertain. Lyophilization inactivates approximately 1 log10 of mouse retrovirus [29] , and this finding is confirmed by our experience with HIV.
Considerable HBV is neutralized by excess anti-HBs [12] , found in virtually every lot of final product. Serendipitous inactivation of HCV is estimated. See Prince et al. [3] for most references. A more recent review [51] will also be available. NA, not available; endog, endogenous experience corresponds well with predicted rates of infectivity based on the known viral load and studies quantitating virus removal/inactivation during processing. During the past decade, no fewer than 12 different approaches directed toward improving the viral safety of coagulation factor concentrates reached the stage where product was placed into clinical evaluation. As a consequence, extensive information is available to permit a good estimate of initial viral loads and of the influence of factors affecting removal and inactivation. As shown in the accompanying analysis, there is a close correspondence between clinical experience related to the transmission of HIV, HBV, and HCV and the predicted probability of safety, thus increasing confidence in the predictions made. This confidence is especially important for HCV, because data are not available about its fractionation characteristics and assumptions had to be made.
Thus, through the development of improved donor and donor blood screening procedures, improved virus sterilization technology, and, in some cases, vigorous purification methodology, the calculated margin of safety for the best of the current Table 2 ). The overall improvement in donor selection, because of public education, donor questionnaires, and new screening tests must also reduce HBV viral load; fivefold is strictly an estimate. A combination of ALT and anti-HCV screening was predicted to decrease NANBHV transmission by 60 percent [47] . When AHF is prepared from anti-HCV screened plasma, a further fivefold reduction might be expected. HCV viral load is reduced by a combination of factors: institution of ALT and anti-HCV testing should reduce the per-unit risk by 60 percent [47] , anti-HCV testing should cause (when performed) a reduction of 80 percent [32] , and a further improvement should occur with improvements in donor selection and a decrease in virus titer associated with remaining infectious units. Line 4: Highly purified concentrates are now beginning to appear. Enhanced purification has been reported to remove up to 10' HIV [34] , though lesser removal may be seen with other viruses, other methods, or in a production setting. frozen plasma (FFP) and cryoprecipitate, even if prepared from plasma pools. With the viral safety of the blood protein derivatives seemingly in hand, the final challenge in providing safe blood products will be the development of procedures to remove or inactivate virus from the cellular components.
